Salmeterol Xinafoate

Suppliers

Names

[ CAS No. ]:
94749-08-3

[ Name ]:
Salmeterol Xinafoate

[Synonym ]:
2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with 4-hydroxy-α-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1)
Salmeterol Xinafoate
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol,1-hydroxynaphthalene-2-carboxylic acid
1-hydroxynaphthalene-2-carboxylic acid - 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol (1:1)
GR 33343G
Salmeterol 1-hydroxy-2-naphthoate
1-Hydroxy-2-naphthoic acid - 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol (1:1)
MFCD00897708
(±)-4-Hydroxy-a1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylate (salt)
Salmeterol (xinafoate)

Chemical & Physical Properties

[ Density]:
1.112g/cm3

[ Boiling Point ]:
603ºC at 760 mmHg

[ Melting Point ]:
137-138ºC

[ Molecular Formula ]:
C36H45NO7

[ Molecular Weight ]:
603.745

[ Flash Point ]:
318.5ºC

[ Exact Mass ]:
603.319580

[ PSA ]:
139.48000

[ LogP ]:
6.74190

[ Index of Refraction ]:
1.565

[ Storage condition ]:
-20°C Freezer

[ Water Solubility ]:
H2O: slightly soluble

MSDS

Click to get detail MSDS

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
S36/37

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

Articles

Safety of bronchial thermoplasty in patients with severe refractory asthma.

Ann. Allergy Asthma Immunol. 111(5) , 402-7, (2013)

Patients with severe refractory asthma treated with bronchial thermoplasty (BT), a bronchoscopic procedure that improves asthma control by reducing excess airway smooth muscle, were followed up for 5 ...

Early intervention with high-dose inhaled corticosteroids for control of acute asthma exacerbations at home and improved outcomes: a randomized controlled trial.

Allergy Asthma Proc. 33(6) , 508-13, (2012)

Various studies have examined the efficacy of a temporary increase in the dose of inhaled corticosteroids (ICSs) during acute asthma exacerbations with conflicting results. This study was designed to ...

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.

Cochrane Database Syst. Rev. 3 , CD006922, (2013)

Epidemiological evidence has suggested a link between beta2-agonists and increased asthma mortality. There has been much debate about possible causal links for this association, and whether regular (d...


More Articles

Related Compounds

  • SalMeterol Xinafoate Adduct IMpurity
  • Salmeterol xinafoate,salmeterol-deoxy-[USP]
  • Salmeterol xinafoate specified impurity C [EP]
  • Salmeterol xinafoate specified impurity E [EP]
  • Salmeterol-d4
  • Salmeterol
  • 4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
  • 1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
  • 2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
  • 1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
  • 5-bromo-2-[[2-(trimethylsilyl)ethoxy]methyl]-2H-Indazole-3-carboxaldehyde
  • (4-Methyl-tetrahydro-furan-2-yl)-methanol
  • N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
  • 4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
  • tert-Butyl-DL-alanine
  • 4-amino-N-[2-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]-N-ethylbenzenesulfonamide